Lance R Mcmahon

List of Publications by Year
in descending order

129 papers	2,538 citations	201674 27 h-index	265206 42 g-index
134 all docs	134 docs citations	134 times ranked	1775 citing authors

#	Article	IF	Citations
1	The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study. Drug Metabolism and Disposition, 2022, 50, 158-167.	3.3	11
2	Evaluation of the terpenes Î²-caryophyllene, Î±-terpineol, and Î³-terpinene in the mouse chronic constriction injury model of neuropathic pain: possible cannabinoid receptor involvement. Psychopharmacology, 2022, 239, 1475-1486.	3.1	17
3	Slow conformational dynamics of the human A2A adenosine receptor are temporally ordered. Structure, 2022, 30, 329-337.e5.	3.3	17
4	In vitro and in vivo pharmacology of kratom. Advances in Pharmacology, 2022, 93, 35-76.	2.0	13
5	Medicinal Cannabis and Central Nervous System Disorders. Frontiers in Pharmacology, 2022, 13, 881810.	3.5	12
6	Effects of Mitragynine and its Active Metabolites on the Reinforcing Effects of Remifentanil and Cocaine in Rats Selfâ€Administering Remifentanil. FASEB Journal, 2022, 36, .	0.5	0
7	Mitragynine Reverses Paclitaxel Chemotherapyâ€Induced Peripheral Neuropathy and is Mediated via Opioid Receptor Involvement. FASEB Journal, 2022, 36, .	0.5	0
8	Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113778.	2.8	10
9	Kratom (Mitragyna speciosa Korth.): A description on the ethnobotany, alkaloid chemistry, and neuropharmacology. Studies in Natural Products Chemistry, 2021, 69, 195-225.	1.8	6
10	Exploring the Chemistry of Alkaloids from Malaysian <i>Mitragyna speciosa</i> (Kratom) and the Role of Oxindoles on Human Opioid Receptors. Journal of Natural Products, 2021, 84, 1034-1043.	3.0	45
11	Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats. Journal of Natural Products, 2021, 84, 1104-1112.	3.0	29
12	Oral Pharmacokinetics in Beagle Dogs of the Mitragynine Metabolite, 7-Hydroxymitragynine. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 459-463.	1.6	3
13	Characterization of a mouse neuropathic pain model caused by the highly active antiviral therapy (HAART) Stavudine. Pharmacological Reports, 2021, 73, 1457-1464.	3.3	1
14	Evaluation of the Terpenes Î²â€caryophyllene, Î±â€terpineol, and Î³â€terpinene in the Mouse Chronic Constriction Injury Model of Neuropathic Pain: Possible Cannabinoid Receptor Involvement. FASEB Journal, 2021, 35, .	0.5	0
15	Pharmacological Characterization of Mitragynine: Antinociception, Respiratory Depression, Selfâ€Administration, Drug Discrimination, Tolerance, and withdrawal in Rats. FASEB Journal, 2021, 35, .	0.5	0
16	Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. Journal of Medicinal Chemistry, 2021, 64, 6523-6548.	6.4	42
17	Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?. Pharmacology Biochemistry and Behavior, 2021, 206, 173192.	2.9	9
18	Activity of <i>Mitragyna speciosa</i> (â€œKratomâ€) Alkaloids at Serotonin Receptors. Journal of Medicinal Chemistry, 2021, 64, 13510-13523.	6.4	30

#	Article	IF	Citations
19	The use of hypercapnic conditions to assess opioid-induced respiratory depression in rats. Journal of Pharmacological and Toxicological Methods, 2021, 111, 107101.	0.7	6
20	Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for<i>Î¼</i>-Opioid Receptor and Opioid-Like Behavioral Effects in Rats. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 410-427.	2.5	52
21	Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. Toxicology Letters, 2020, 319, 148-154.	0.8	36
22	Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2020, 180, 113019.	2.8	14
23	Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids. Journal of Medicinal Chemistry, 2020, 63, 433-439.	6.4	92
24	Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. Planta Medica, 2020, 86, 1278-1285.	1.3	19
25	Nicotinic Acetylcholine Receptor Accessory Subunits Determine the Activity Profile of Epibatidine Derivatives. Molecular Pharmacology, 2020, 98, 328-342.	2.3	10
26	Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy. ACS Pharmacology and Translational Science, 2020, 3, 1063-1068.	4.9	36
27	Evaluation of the rewarding effects of mitragynine and 7â€hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. Drug and Alcohol Dependence, 2020, 215, 108235.	3.2	19
28	Current and Future Potential Impact of COVID-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use. Frontiers in Psychiatry, 2020, 11, 574483.	2.6	5
29	Alterations in mouse spinal cord and sciatic nerve microRNAs after the chronic constriction injury (CCI) model of neuropathic pain. Neuroscience Letters, 2020, 731, 135029.	2.1	12
30	Unexpected loss of sensitivity to the nicotinic acetylcholine receptor antagonist activity of mecamylamine and dihydroâ€Î²â€erythroidine in nicotineâ€tolerant mice. Brain and Behavior, 2020, 10, e01581.	2.2	2
31	Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators. Neuropharmacology, 2020, 168, 108008.	4.1	17
32	Axially Chiral Cannabinols: A New Platform for Cannabinoidâ€Inspired Drug Discovery. ChemMedChem, 2020, 15, 728-732.	3.2	6
33	Potential Contribution of 7â€Hydroxymitragynine, a Metabolite of the Primary Kratom (Mitragyna) Tj ETQq1 1 0.784314 rgBT /Overlock 1-1.	0.5	5
34	The discriminative stimulus effects of epibatidine in C57BL/6J mice. Behavioural Pharmacology, 2020, 31, 565-573.	1.7	0
35	The Adrenergic a 2 Receptorâ€Mediated Discriminativeâ€Stimulus Effects of Mitragynine, the Primary Alkaloid in Kratom (Mitragyna Speciosa) in Rats. FASEB Journal, 2020, 34, 1-1.	0.5	5
36	The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 380-389.	2.5	6

#	Article	IF	Citations
37	Kratom policy: The challenge of balancing therapeutic potential with public safety. International Journal of Drug Policy, 2019, 70, 70-77.	3.3	83
38	The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats. Psychopharmacology, 2019, 236, 2725-2734.	3.1	40
39	Tolerance and dependence to Î”9-tetrahydrocannabinol in rhesus monkeys: Activity assessments. PLoS ONE, 2019, 14, e0209947.	2.5	8
40	Nicotine-like discriminative stimulus effects of acetylcholinesterase inhibitors and a muscarinic receptor agonist in Rhesus monkeys. Drug Development and Industrial Pharmacy, 2019, 45, 861-867.	2.0	2
41	Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms. Pharmacology Biochemistry and Behavior, 2019, 179, 27-33.	2.9	7
42	Differential cross-tolerance to the effects of nicotinic acetylcholine receptor drugs in C57BL/6J mice following chronic varenicline. Behavioural Pharmacology, 2019, 30, 412-421.	1.7	3
43	Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics. Expert Review of Clinical Pharmacology, 2019, 12, 189-195.	3.1	6
44	Pharmacological Characterization of Mitragynine, the Primary Constituent in Kratom (Mitragyna) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.5	0
45	Rapid nicotine tolerance and cross-tolerance to varenicline in rhesus monkeys: Drug discrimination.. Experimental and Clinical Psychopharmacology, 2018, 26, 541-548.	1.8	5
46	The contribution of Î±4Î²2 and non-Î±4Î²2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice. Psychopharmacology, 2017, 234, 781-792.	3.1	27
47	The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA 2 analysis with dihydro-Î²-erythroidine. Neuropharmacology, 2017, 116, 9-17.	4.1	8
48	Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 278-286.	2.5	19
49	Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists. Behavioural Pharmacology, 2016, 27, 240-248.	1.7	9
50	Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice. European Journal of Pharmacology, 2016, 786, 169-178.	3.5	12
51	Attenuated nicotineâ€like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily. British Journal of Pharmacology, 2016, 173, 3454-3466.	5.4	3
52	Enhanced discriminative stimulus effects of Î”9-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys. Drug and Alcohol Dependence, 2016, 165, 87-93.	3.2	13
53	Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 111-120.	2.5	33
54	Simultaneous Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Shares Discriminative Stimulus Effects with Î”9-Tetrahydrocannabinol in Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 261-268.	2.5	22

#	Article	IF	Citations
55	The rise (and fall?) of drug discrimination research. Drug and Alcohol Dependence, 2015, 151, 284-288.	3.2	19
56	Hypothermic Effects of Î” 9 â€THC and Nicotine in Kynurenineâ€3â€Monooxygenase (KMO) Knockout Mice. FASEB Journal, 2015, 29, LB491.	0.5	0
57	Characterization of a Nicotine Discriminative Stimulus in Rhesus Monkeys. FASEB Journal, 2015, 29, 1019.5.	0.5	0
58	The Discriminative Stimulus Effects of Nicotine, Epibatidine, and Varenicline in Mice: Involvement of Î²2 Containing Nicotinic Acetylcholine Receptor Subtypes. FASEB Journal, 2015, 29, 1019.3.	0.5	0
59	The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys. Behavioural Pharmacology, 2014, 25, 296-305.	1.7	8
60	Blood levels do not predict behavioral or physiological effects of Î”9-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure. Drug and Alcohol Dependence, 2014, 139, 1-8.	3.2	18
61	JWH-018 in rhesus monkeys: Differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects. European Journal of Pharmacology, 2014, 740, 151-159.	3.5	26
62	Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice. Psychopharmacology, 2014, 231, 4455-4466.	3.1	16
63	The cannabinoid agonist HU-210: Pseudo-irreversible discriminative stimulus effects in rhesus monkeys. European Journal of Pharmacology, 2014, 727, 35-42.	3.5	15
64	Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids. Psychopharmacology, 2013, 228, 321-333.	3.1	18
65	Inhibition of both FAAH and MAGL, but not either separately, produces deltaâ€9â€THC like discriminative stimulus effects. FASEB Journal, 2013, 27, 1097.7.	0.5	0
66	Discriminative stimulus effects of the synthetic cannabinoid JWHâ€018 in rhesus monkeys. FASEB Journal, 2013, 27, 1097.6.	0.5	1
67	Apparent Inverse Relationship between Cannabinoid Agonist Efficacy and Tolerance/Cross-Tolerance Produced by Î”⁹-Tetrahydrocannabinol Treatment in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 843-849.	2.5	47
68	JWH-018 and JWH-073: Î”⁹-Tetrahydrocannabinol-Like Discriminative Stimulus Effects in Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 37-45.	2.5	62
69	Pharmacologic Characterization of a Nicotine-Discriminative Stimulus in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 840-849.	2.5	27
70	Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 260-269.	4.8	60
71	Purity of Synthetic Cannabinoids Sold Online for Recreational Use. Journal of Analytical Toxicology, 2012, 36, 66-68.	2.8	81
72	Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys. Psychopharmacology, 2012, 222, 425-438.	3.1	16

#	Article	IF	Citations
73	Tolerance and crossâ€tolerance produced by deltaâ€9â€tetrahydrocannabinol treatment in rhesus monkeys. FASEB Journal, 2012, 26, 660.6.	0.5	0
74	Chronic Î”⁹â€tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and crossâ€tolerance among cannabinoids. British Journal of Pharmacology, 2011, 162, 1060-1073.	5.4	26
75	The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys. British Journal of Pharmacology, 2011, 164, 655-666.	5.4	16
76	The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: Differences in Î±4Î²2 nicotinic receptor activation. European Journal of Pharmacology, 2011, 654, 47-52.	3.5	25
77	Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology, 2011, 215, 665-675.	3.1	19
78	Quantification of Rimonabant (SR 141716A) in Monkey Plasma Using HPLC with UV Detection. Journal of Chromatographic Science, 2010, 48, 491-495.	1.4	3
79	Rimonabant-Induced Î”9-Tetrahydrocannabinol Withdrawal in Rhesus Monkeys: Discriminative Stimulus Effects and Other Withdrawal Signs. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 347-356.	2.5	41
80	In vivo pharmacology of endocannabinoids and their metabolic inhibitors: Therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins and Other Lipid Mediators, 2010, 91, 90-103.	1.9	31
81	Nicotine and varenicline share discriminative stimulus properties and act through mecamylamineâ€sensitive receptors in rhesus monkeys.. FASEB Journal, 2010, 24, .	0.5	0
82	Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Î”9-tetrahydrocannabinol. Psychopharmacology, 2009, 203, 219-228.	3.1	20
83	Some effects of dopamine transporter and receptor ligands on discriminative stimulus, physiologic, and directly observable indices of opioid withdrawal in rhesus monkeys. Psychopharmacology, 2009, 203, 411-420.	3.1	5
84	Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. International Review of Psychiatry, 2009, 21, 134-142.	2.8	33
85	Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Î”9-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology, 2008, 198, 487-495.	3.1	43
86	Interactions between Î”9-tetrahydrocannabinol and Î¼ opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology, 2008, 199, 199-208.	3.1	57
87	Acute cross tolerance to midazolam, and not pentobarbital and pregnanolone, after a single dose of chlordiazepoxide in monkeys discriminating midazolam. Behavioural Pharmacology, 2008, 19, 796-804.	1.7	10
88	Neurosteroids in Alcohol and Substance Use. , 2008, , 509-538.		1
89	Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. European Journal of Pharmacology, 2007, 569, 70-76.	3.5	51
90	Changes in relative potency among positive GABAA receptor modulators upon discontinuation of chronic benzodiazepine treatment in rhesus monkeys. Psychopharmacology, 2007, 192, 135-145.	3.1	15

#	Article	IF	Citations
91	Comparison of naltrexone, 6Î±-naltrexol, and 6Î²-naltrexol in morphine-dependent and in nondependent rhesus monkeys. Psychopharmacology, 2007, 195, 479-486.	3.1	17
92	Quantification of rimonabant (SR 141716A) in plasma using HPLC with UV detection. FASEB Journal, 2007, 21, A417.	0.5	0
93	Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): Dependence liability studies.. Behavioral Neuroscience, 2006, 120, 535-541.	1.2	24
94	Differential behavioral effects of low efficacy positive GABAA modulators in combination with benzodiazepines and a neuroactive steroid in rhesus monkeys. British Journal of Pharmacology, 2006, 147, 260-268.	5.4	19
95	Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Î"9-tetrahydrocannabinol. Psychopharmacology, 2006, 188, 306-314.	3.1	27
96	Characterization of Cannabinoid Agonists and Apparent pA2 Analysis of Cannabinoid Antagonists in Rhesus Monkeys Discriminating Î"9-Tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1211-1218.	2.5	47
97	Efficacy and the Discriminative Stimulus Effects of Negative GABAA Modulators, or Inverse Agonists, in Diazepam-Treated Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 907-913.	2.5	3
98	Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys. Behavioural Pharmacology, 2005, 16, 53-58.	1.7	9
99	SR 141716A differentially attenuates the behavioral effects of ??9-THC in rhesus monkeys. Behavioural Pharmacology, 2005, 16, 363-372.	1.7	29
100	Relationship of cocaine-induced c-Fos expression to behaviors and the role of serotonin 5-HT2A receptors in cocaine-induced c-Fos expression.. Behavioral Neuroscience, 2005, 119, 1173-1183.	1.2	21
101	Cross-tolerance and Î¼ agonist efficacy in pigeons treated with LAAM or buprenorphine. Pharmacology Biochemistry and Behavior, 2005, 81, 626-634.	2.9	6
102	Inez Beverly Prosser and the education of African Americans. Journal of the History of the Behavioral Sciences, 2005, 41, 43-62.	0.7	10
103	Combined discriminative stimulus effects of midazolam with other positive GABAA modulators and GABAA receptor agonists in rhesus monkeys. Psychopharmacology, 2005, 178, 400-409.	3.1	30
104	Negative GABAA modulators attenuate the discriminative stimulus effects of benzodiazepines and the neuroactive steroid pregnanolone in rhesus monkeys. Psychopharmacology, 2005, 181, 697-705.	3.1	5
105	Cocaine and Other Indirect-Acting Monoamine Agonists Differentially Attenuate a Naltrexone Discriminative Stimulus in Morphine-Treated Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 111-119.	2.5	14
106	Stereoselective discriminative stimulus effects of zopiclone in rhesus monkeys. Psychopharmacology, 2003, 165, 222-228.	3.1	11
107	Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and Î³-butyrolactone in rhesus monkeys. European Journal of Pharmacology, 2003, 466, 113-120.	3.5	14
108	Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens. Neuropharmacology, 2003, 44, 342-353.	4.1	55

#	Article	IF	Citations
109	Discriminative stimulus effects of (âˆ’)-ephedrine in rats: analysis with catecholamine transporter and receptor ligands. Drug and Alcohol Dependence, 2003, 70, 255-264.	3.2	13
110	Relative Efficacy of Buprenorphine, Nalbuphine and Morphine in Opioid-Treated Rhesus Monkeys Discriminating Naltrexone. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 1167-1173.	2.5	10
111	Discriminative Stimulus Effects of Positive GABAAModulators and Other Anxiolytics, Sedatives, and Anticonvulsants in Untreated and Diazepam-Treated Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 109-120.	2.5	10
112	Discriminative Stimulus Effects of the Cannabinoid Antagonist, SR 141716A, in Î”â¹-Tetrahydrocannabinol-Treated Rhesus Monkeys.. Experimental and Clinical Psychopharmacology, 2003, 11, 286-293.	1.8	14
113	Daily Treatment with Diazepam Differentially Modifies Sensitivity to the Effects of Î³-Aminobutyric AcidA Modulators on Schedule-Controlled Responding in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 1017-1025.	2.5	22
114	Reactions of Trifluoromethylsulfenyl Chloride with 1,5-Cyclooctadiene. Phosphorus, Sulfur and Silicon and the Related Elements, 2002, 177, 1117-1125.	1.6	8
115	Discriminative Stimulus Effects of Benzodiazepine (BZ)1 Receptor-Selective Ligands in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 505-512.	2.5	12
116	Acute and chronic effects of the neuroactive steroid pregnanolone on schedule-controlled responding in rhesus monkeys. Behavioural Pharmacology, 2002, 13, 545-555.	1.7	21
117	Differential Regulation of the Mesoaccumbens Circuit by Serotonin 5-Hydroxytryptamine (5-HT)_{2A}and 5-HT_{2C}Receptors. Journal of Neuroscience, 2001, 21, 7781-7787.	3.6	126
118	Role of 5-HT2A and 5-HT2B/2C Receptors in the Behavioral Interactions Between Serotonin and Catecholamine Reuptake Inhibitors. Neuropsychopharmacology, 2001, 24, 319-329.	5.4	26
119	Effects of Ephedrine Enantiomers on Conditioned Taste Aversion and Kaolin Intake in Rats. Pharmacology Biochemistry and Behavior, 1999, 63, 119-124.	2.9	4
120	Effects of (-)-ephedrine on locomotion, feeding, and nucleus accumbens dopamine in rats. Psychopharmacology, 1998, 135, 133-140.	3.1	28
121	Repeated administration of ephedrine induces behavioral sensitization in rats. Psychopharmacology, 1998, 140, 52-56.	3.1	13
122	Basic Measures of Food Intake. Current Protocols in Neuroscience, 1998, 3, 8.6B.1-8.6B.8.	2.6	0
123	Effects of the Î±1a-Adrenoceptor Antagonist RS-17053 on Phenylpropanolamine-Induced Anorexia in Rats. Pharmacology Biochemistry and Behavior, 1997, 57, 281-284.	2.9	7
124	Assessment of the Role of Oxytocin Receptors in Phenylpropanolamine-Induced Anorexia in Rats. Pharmacology Biochemistry and Behavior, 1997, 57, 767-770.	2.9	2
125	Decreased Intake of a Liquid Diet in Nonfood-Deprived Rats Following Intra-PVN Injections of GLP-1 (7â€“36) Amide. Pharmacology Biochemistry and Behavior, 1997, 58, 673-677.	2.9	39
126	Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus. Physiology and Behavior, 1996, 59, 63-69.	2.1	11

#	Article	IF	Citations
127	Conditioned taste aversion in rats induced by the Î±1-adrenoceptor agonist cirazoline. Pharmacology Biochemistry and Behavior, 1994, 48, 601-604.	2.9	1
128	Modulation of feeding by hypothalamic paraventricular nucleus Î±1- and Î±2-adrenergic receptors. Life Sciences, 1993, 53, 669-679.	4.3	115
129	Effects on food and water intake of the Î±1-adrenoceptor agonists amidephrine and SK&F-89748. Life Sciences, 1993, 53, 169-174.	4.3	18